Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are sometimes taken off-label for weight loss.

Compounded semaglutide is a non-FDA-approved alternative to products that contain semaglutide, such as Ozempic. Learn how the safety and efficacy of compounded semaglutide compares with Ozempic.

Common Side Effects of Semaglutide. It’s not uncommon to experience some adverse effects with semaglutide, especially during the first few weeks of treatment or when adjusting to a higher dose.

The average changes with semaglutide and liraglutide were -5.1% and -2.2%, respectively. In patients receiving T2D medication, the mean change was -3.2% as compared to -5.9% of those who were ...

Compounded semaglutide, ubiquitous online, has certainly stepped into the void to make this therapy more accessible to the general public. But in the process, ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the ...

Researchers discovered semaglutide—the active ingredient in Ozempic and Wegovy—may reduce the risk of death and lower the chance of developing cardiovascular conditions like stroke and heart ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of ...

The semaglutide group achieved a weight loss of 10.5% at 72 weeks compared with 2% for adults receiving placebo (estimated difference, –8.5 percentage points; 95% CI, –9.6 to –7.4; P < .001).

There have been 159 calls to national poison control centers so far this year involving compounded GLP-1s, the class of medications that includes semaglutide. In 2023, there were only 32.